Complementary and alternative medicine use in adults with autism spectrum disorder in Germany: results from a multi-center survey

Juliana Höfer1*, Falk Hoffmann1, Inge Kamp-Becker2, Charlotte Küpper3, Luise Poustka4, Stefan Roepke3, Veit Roessner5, Sanna Stroth2, Nicole Wolff5 and Christian J. Bachmann6

Abstract

Background: Complementary and Alternative Medicine (CAM) is widely used both in the general population and for the treatment of somatic and psychiatric disorders. Studies on CAM use among patients with autism spectrum disorder (ASD) have so far only focused on children and adolescents. The aim of this study was to investigate patterns of CAM use among adults with ASD.

Methods: A questionnaire survey concerning current and lifetime use of CAM was distributed to adults with ASD between November 2015 and June 2016. Participants diagnosed by experienced clinicians using the current diagnostic gold standard were recruited from four ASD outpatient clinics in Germany. Questionnaire data was then linked to supplementary clinical data.

Results: The final sample consisted of 192 adults (response: 26.8%) with a mean age of 31.5 years (80% male; diagnoses: Asperger’s syndrome (58%), childhood autism (27%), atypical autism (12%)). 45% of the respondents stated that they were currently using or had used at least one CAM modality in their life. Among the participants with lifetime CAM use, almost half had used two or more different types of CAM. Alternative medical systems (e.g. homeopathy, acupuncture) were most frequently used, followed by mind-body interventions (e.g. yoga, biofeedback, animal assisted therapy). Overall, 20% of respondents stated that they would like to try at least one listed CAM modality in the future.

Conclusions: This is the first study on CAM use in adults with ASD, demonstrating considerable CAM use in this population. Given the popularity of CAM, patients should be informed about the effectiveness and potentially dangerous side effects of CAM treatments, as evidence for the majority of CAM methods in ASD is still limited.

Keywords: Autism spectrum disorder, Autism, Complementary and alternative medicine, CAM, Prevalence, Adults, Germany

Introduction

The term “Complementary and Alternative Medicine (CAM)” denotes a heterogeneous group of diverse medical and health care practices that are not considered to be part of conventional health care systems [1]. Complementary medicine is typically defined as nontraditional practices that are used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine [2].

The utilisation of CAM is widespread, both in healthy individuals and those with somatic or psychiatric disorders. In a systematic review of 49 studies from 15 countries, the prevalence of CAM use in the general population ranged from 10 to 76% [3], with the large variance being due to geographical, economic, social, cultural and methodological factors. However, several studies have demonstrated that typical CAM users are likely to be female, better educated and to have a higher income [4–9].
CAM therapies are also used for the treatment of many physical as well as mental disorders, and especially those of a more chronic nature, e.g. cancer, asthma, depression or autism spectrum disorders (ASD) [10]. Compared to the general population, the utilization of CAM is higher amongst individuals with these disorders [4, 5, 7, 11–14].

ASD is a neurodevelopmental disorder which is characterized by pervasive difficulties in interaction and communication that are accompanied by unusually restricted, repetitive behavior and interests since early childhood [15, 16]. It is a high-cost and lifelong condition that affects up to 1% of adults [17]. For children, the prevalence was 16.8 per 1000 children in 2014 [18], with prevalences steadily increasing in recent decades [19–21]. To date, no causal treatment for ASD is known, but there exist various medical, behavioral and educational interventions that aim to mitigate the core deficits related to the disorder, and to improve psychiatric comorbidity [16]. Comorbid symptoms of ASD such as hyperactivity, anxiety, aggression, or insomnia, are frequently treated with both conventional therapies, including psychopharmacological agents, and CAM therapies [10, 22].

While there is limited evidence for the effectiveness of some types of CAM for the treatment of ASD core symptoms and associated comorbidities [23, 24], most CAM treatments have not yet been adequately studied for this indication [25].

Although many CAM modalities are noninvasive and free from side effects (e.g. yoga or music therapy), there are some types of CAM, such as chelating agents or megavitamin therapy, for which safety concerns exist due to potentially dangerous side effects. Furthermore, knowledge on pharmacological interaction effects between CAM therapies and psychotropic drugs is scarce [26–29], and some treatments (e.g. special diets) might be associated with potentially harmful, long-term side effects, such as nutritional deficits [25].

Despite the limited evidence for CAM use in ASD, a recent systematic review yielded relatively high prevalences of CAM use in children and adolescents with ASD, ranging from 28 to 95% (median: 54%), with special diets or dietary supplements (including vitamins) being the most frequent CAM treatments [10]. However, none of the surveys covered by the afore-mentioned review was conducted in adults with ASD. Therefore, the aim of the present study was to investigate prevalence and type of CAM use among adults with a diagnosis of ASD.

Methods

This study was conducted as a part of a large clinical and research network, the ASD-Net, which is funded by the German federal ministry of education and research (BMBF), and which focuses on the key challenges in ASD diagnostics, therapy and health service research [21].

Recruitment and participants

Data for this study was collected in four academic ASD outpatient clinics in Germany (Berlin, Dresden, Mannheim, and Marburg). Between November 2015 and June 2016, these study centers recruited adults with an ASD diagnosis, who received services from or had been diagnosed at one of these outpatient clinics. Patients were included if they were 18 years or older, and had a confirmed diagnosis of ASD according to ICD-10 (F84.0, F84.1, F84.5, F84.8, F84.9). Regarding the classification of ASD diagnoses in this study, it should be noted that, unlike the DSM-5, the ICD-10 has not incorporated the concept of autism as a “spectrum disorder”, and therefore offers different diagnostic categories for patients with autism (e.g. “atypical autism” (F84.1), which is equivalent to PDD-NOS in DSM-IV (299.80)). All participants were diagnosed by experienced clinicians using the current diagnostic gold standard in ASD, the Autism Diagnostic Observation Schedule (ADOS) and – if parents were available – the Autism Diagnostic Interview-Revised (ADI-R) [21, 30, 31].

Questionnaire and data collection

Based on the Client Service Receipt Inventory (CSRI) [32], a self-administered questionnaire on sociodemographic data (including educational level), and health and social service use, including CAM, was developed and has been mailed to the participants. In exceptional cases, the questionnaire was handed over personally. Each questionnaire was accompanied by a cover letter, a participant information sheet and a written informed consent form, in which participants could consent to data linkage between their questionnaire data and their clinical data (e.g. age, sex, ICD 10-diagnosis, IQ).

The questionnaire item on CAM use was configured as follows: Following the classification of the National Center for Complementary and Integrative Health (NCCIH), we listed five CAM categories: [1] Alternative medical systems or complete systems of therapy and practice (e.g. acupuncture), [2] mind-body interventions (e.g. yoga), [3] biologically based therapies (e.g. diets), [4] manipulative and body based methods (e.g. craniosacral therapy), and [5] other CAM practices (e.g. quigong) [33]. For each of the five categories (a non-exhaustive list of examples was provided), participants could mark one of the following response options: “Yes, I use this CAM category currently”, “Yes, I used in the past”, “I would like to try it”, or “No”.

Participants’ level of education was defined in accordance with the International Standard Classification of Education (ISCED) [34, 35], and classified into three groups: low (ISCED level 0–2B), medium (level 2A) and high education (level 3A). Referring to the German school system, low educational level complies with 9
years of schooling or leaving school without having acquired any school-leaving qualification. Medium educational level is equivalent to 10 years of schooling, and high educational level complies with 12 or 13 years of schooling and a school-leaving qualification, which opens access to higher education institutions [36, 37].

The IQ was assessed using the German versions of the following instruments: Wechsler Intelligence Scale for Children (WISC-R [38], WISC-III [39], WISC-IV [40]), Wechsler Adult Intelligence Scale (WAIS-R [41], WAIS-III [42]), Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III [43]), Kaufman Assessment Battery for Children [44], Wortschatztest [45], Raven’s Standard Progressive Matrices [46], and Raven’s Coloured Progressive Matrices [47]. According to ICD-10, the level of intellectual functioning was classified into two groups: learning disability or intellectual disability (IQ < 85) vs no learning disability or intellectual disability (IQ ≥ 85).

Data from the questionnaires were entered by one person in an electronic Case Report Form (eCRF) created in OpenClinica* (OpenClinica Enterprise Version: 3.3), and were checked by a second person.

Baseline data were analysed using descriptive statistics. The prevalence of CAM use in the study population was stratified by age (18–24, 25–34, ≥35 years), sex (male, female), ASD subgroup (Asperger syndrome, other ASD diagnoses), intellectual functioning (IQ < 85, IQ ≥ 85) and educational level (low, medium, high).

To calculate 95% confidence intervals (95% CIs), the Clopper-Pearson Exact method was applied. Additionally, the association between CAM use and the above mentioned predictors was evaluated in a logistic regression model; with odds ratios (OR) and 95% CIs being inferred. All statistical analyses were performed with SAS, version 9.4 (SAS Institute, Cary, USA).

The study protocol was reviewed and approved by the Commission for Research Impact Assessment and Ethics, Carl von Ossietzky University Oldenburg, and by the respective ethic committees of the participating study sites.

### Results

#### Baseline characteristics

Survey documents were sent to 782 adults with ASD. In 52 cases, mailings could not be delivered due to a wrong address. Two hundred and six persons returned the questionnaire including a signed written consent form (response: 26.8%), but in 10 cases clinical data for linkage was not available. Of the remaining 196 participants, 192 answered at least one CAM-related question and were thus included as study population. 22.2% of the adult non-responders and 31.8% of the responders were aged ≥35 years. The baseline characteristics of the study population are presented in Table 1. Most of the participants were male (79.7%), and the mean age was 31.5 years (range: 18–67 years). The most frequent diagnosis was Asperger syndrome (57.8%), followed by childhood autism (27.1%), and atypical autism (12.0%). More than two thirds of the study population were of average or above average intelligence (69.7%), and nearly half had a high level of education (44.3%).

### Overall CAM use

Overall, 44.8% of the respondents stated that they were currently using, or had used at least one CAM modality in their life (Table 2). Almost 30% of the sample reported current CAM use, and 24.5% indicated that they had used some type of CAM in the past.

The three types of CAM use prevalence (lifetime, current, past), stratified by sex, age, clinical diagnosis, intellectual functioning, and level of education are presented in Table 2. Regarding lifetime prevalence, participants aged 35 years or older (50.8%), were more likely to have used CAM, compared to those younger than 35 years (44.1% vs. 40.3%, respectively). Females (48.7%), and patients with a diagnosis of Asperger syndrome (46.9%) reported slightly more frequent lifetime use of CAM than males (43.8%) respectively than patients with other ASD

---

### Table 1 Baseline characteristics

| Characteristics (number of respondents*) | n   | %   |
|-----------------------------------------|-----|-----|
| Sex (n = 192)                           |     |     |
| Male                                   | 153 | 79.7|
| Female                                 | 39  | 20.3|
| Mean age (in years) (±SD; range)        | 31.5| (10.9; 18–67) |
| Age groups (in years) (n = 192)         |     |     |
| 18–24                                  | 59  | 30.7|
| 25–34                                  | 72  | 37.5|
| ≥35                                    | 61  | 31.8|
| Diagnoses (n = 192)                    |     |     |
| Childhood autism (F84.0)               | 52  | 27.1|
| Atypical autism (F84.1)                | 23  | 12.0|
| Asperger syndrome (F84.5)              | 111 | 57.8|
| Other specified pervasive developmental disorders (F84.8) | 1 | 0.5 |
| Pervasive developmental disorder, not otherwise specified (F84.9) | 5 | 2.6 |
| Intellectual functioning (n = 178)     |     |     |
| IQ < 85                                | 54  | 30.3|
| IQ ≥ 85                                | 124 | 69.7|
| Level of education (n = 192)           |     |     |
| Low                                    | 56  | 29.2|
| Medium                                 | 51  | 26.6|
| High                                   | 85  | 44.3|

*due to missing values, figures may differ
Table 2 Stratified prevalence of lifetime, current, and past CAM use, and of willingness to try CAM

| Sex          | lifetime use³ | Prevalence in % (95% CI) | current use | past use | willingness to try³³ |
|--------------|---------------|--------------------------|-------------|---------|----------------------|
| Male         | 43.8 (35.8–52.0) | 27.5 (20.6–35.2) | 24.2 (17.6–31.8) | 20.3 (14.2–27.5) |
| Female       | 48.7 (32.4–65.2) | 33.3 (19.1–50.2) | 25.6 (13.0–42.1) | 17.9 (7.5–33.5) |

Age groups (in years)

| Age groups (in years) | Prevalence in % (95% CI) | current use | past use | willingness to try³³ |
|-----------------------|--------------------------|-------------|---------|----------------------|
| 18–24                 | 44.1 (31.2–57.6) | 20.3 (11.0–32.8) | 32.2 (20.6–45.6) | 10.2 (3.8–20.8) |
| 25–34                 | 40.3 (28.9–52.5) | 30.6 (20.2–42.5) | 18.1 (10.0–28.9) | 20.8 (12.2–32.0) |
| ≥ 35                  | 50.8 (37.7–63.9) | 34.4 (22.7–47.7) | 24.6 (14.5–37.3) | 27.9 (17.1–40.8) |

Diagnoses

| Diagnoses          | Prevalence in % (95% CI) | current use | past use | willingness to try³³ |
|--------------------|--------------------------|-------------|---------|----------------------|
| Other ASD diagnosis | 42.0 (31.1–53.5) | 28.4 (18.9–39.5) | 22.2 (13.7–32.8) | 21.0 (12.7–31.5) |
| Asperger syndrome  | 46.8 (37.3–56.6) | 28.8 (20.6–38.2) | 26.1 (18.2–35.3) | 18.9 (12.1–27.5) |

Intellectual functioning

| Intellectual functioning | Prevalence in % (95% CI) | current use | past use | willingness to try³³ |
|-------------------------|--------------------------|-------------|---------|----------------------|
| IQ  < 85                | 42.6 (29.2–56.8) | 31.5 (19.5–45.6) | 25.9 (15.0–39.7) | 16.7 (7.9–29.3) |
| IQ  ≥ 85                | 42.7 (33.9–51.9) | 27.4 (19.8–36.2) | 21.0 (14.2–29.2) | 21.0 (14.2–29.2) |

Level of education

| Level of education | Prevalence in % (95% CI) | current use | past use | willingness to try³³ |
|--------------------|--------------------------|-------------|---------|----------------------|
| Low                | 44.6 (31.3–58.5) | 32.1 (20.3–46.0) | 25.0 (14.4–38.4) | 17.9 (8.9–30.4) |
| Medium             | 41.2 (27.6–55.8) | 23.5 (12.8–37.5) | 27.5 (15.9–41.7) | 9.8 (3.3–21.4) |
| High               | 47.1 (36.1–58.2) | 29.4 (20.0–40.3) | 22.4 (14.0–32.7) | 27.1 (18.0–37.8) |
| Overall            | 44.8 (37.6–52.1) | 28.6 (22.4–35.6) | 24.5 (18.6–31.2) | 19.8 (14.4–26.1) |

³contains all respondents who stated current use, past use or both
³³contains also respondents who stated that they already use or have used some other CAM modality

diagnoses (42.0%). Stratified by educational level, lifetime use was highest in patients with a high school-leaving qualification (47.1%). Stratification of lifetime CAM use by intellectual functioning did not reveal any differences.

In a multivariate logistic regression using sex, age, type of diagnosis, intellectual functioning, and educational level as predictors of lifetime CAM use, none of the predictors were significant.

CAM modalities

Among the participants with lifetime CAM-use, almost half (46.5%) had used treatments from two or more different categories of CAM. As shown in Table 3, the most commonly used categories were “alternative medical systems or complete systems of therapy and practice” (26.9%), e.g. homeopathy, acupuncture or Traditional Chinese Medicine, and “mind-body interventions” (23.6%), e.g. yoga, music therapy, biofeedback, or animal assisted therapy.

Regarding current CAM use, the modality most frequently used was “Biologically Based Therapies” (14.2%), while “Alternative medical systems or complete systems of therapy and practice” (16.1%) were the most common modality in the past use category.

Regarding lifetime use, no notable differences between the five CAM categories according to sex, age, diagnosis, intellectual functioning, or educational level were found (Table 4).

Willingness to try CAM

Of the 192 participants, 19.8% stated that they would like to try at least one listed CAM modality in the future, including respondents who stated that they already use or had used another CAM method listed in the questionnaire. 6.3% of the respondents had not yet used any type of CAM but would like to try it. Willingness to try CAM increased with higher age (10.2% vs. 20.8% vs. 27.9%, respectively), and respondents with a high level of education (27.1%) were more frequently interested in trying CAM than those with a lower educational level (medium: 9.8%, low: 17.9%).

Discussion

In this study, 44.8% of the responding adults with ASD stated that they are currently using or had used at least one CAM modality in their life.

As this study is the first of its kind, its results can only be compared to studies with non-autistic adults. As mentioned in the introduction, the prevalence of CAM use in the general population is estimated to be between 10 and 76% [3]. For Germany, a systematic review found the prevalence of CAM use ranging from 40 to 62% in the general population [48].

Regarding CAM use in psychiatric disorders in general, de Jonge et al. [49] studied the prevalence of “CAM contact” in adults with a range of mental disorders in 25
high-income countries \((N = 138,801)\), drawing on representational data from the World Mental Health Surveys (studied period: 2001–2012). In their study, they found an overall CAM use prevalence of 4.6%. When including only those individuals with severe behavioral disorders receiving specialist psychiatric care, CAM use increased to 22.5%. However, de Jonge et al. used a different, possibly narrower, definition of CAM which could account for the lower percentage of usage found in their study. Still, this figure is only half of the prevalence measured in this study. Nevertheless, other population-based studies from western countries on CAM use for the treatment of psychiatric disorders found higher utilisation: A large review that included 45 publications on

Table 3 Prevalence of lifetime, current, past use and willingness to try different CAM categories

| CAM category 1 | Lifetime use | Current use | Past use | Willingness to try |
|----------------|--------------|-------------|----------|--------------------|
| CAM group 1: Alternative Medical Systems or complete systems of therapy and practice (e.g. Anthroposophic medicine, homeopathy, naturopathic medicine, Traditional Chinese Medicine, acupuncture) | 26.9 (20.7–33.9) | 10.8 (6.7–16.1) | 16.1 (11.2–22.2) | 4.8 (2.2–9.0) |
| CAM group 2: Mind-Body Interventions (e.g. yoga, biofeedback, music therapy, dance therapy, meditation, animal-assisted therapy, prayer and spiritual healing) | 23.6 (17.7–30.5) | 13.2 (8.6–19.0) | 10.4 (6.4–15.8) | 9.9 (6.0–15.2) |
| CAM group 3: Biologically Based Therapies (e.g. special diets (e.g. gluten free, casein free), dietary supplements, melatonin, naltrexone, vitamin C, vitamin B6/magnesium, amino 3 fatty acids, trace elements, secretin, chelation therapy, hyperbaric oxygen therapy) | 17.6 (12.3–24.1) | 14.2 (9.4–20.3) | 3.4 (1.3–7.3) | 5.1 (2.4–9.5) |
| CAM group 4: Manipulative and Body Based Methods (e.g. facilitated communication, PECS, chiropractic, osteopathy, craniosacral therapy, sensory integration therapy or auditory integration training, Bobath) | 15.3 (10.4–21.5) | 6.3 (3.2–10.9) | 9.1 (5.3–14.3) | 10.2 (6.2–15.7) |
| CAM group 5: Other CAM Practices (e.g. energy medicine, Feldenkrais, Pilates, Qigang, Reiki) | 3.5 (1.3–7.5) | 1.8 (0.4–5.0) | 1.8 (0.4–5.0) | 11.1 (6.8–16.8) |

CAM - complementary and alternative medicine, CI - confidence interval, PECS - picture exchange communication system.

Table 4 Stratified prevalence of lifetime use of different CAM categories

| CAM category 1 | CAM category 2 | CAM category 3 | CAM category 4 | CAM category 5 |
|----------------|--------------|--------------|--------------|--------------|
| Sex Male | 26.5 (19.6–34.4) | 25.9 (19.0–33.7) | 15.7 (10.1–22.8) | 15.0 (9.5–22.0) | 2.9 (0.8–7.4) |
| Female | 28.2 (15.0–44.9) | 14.3 (4.8–30.3) | 25.0 (12.1–42.2) | 16.7 (6.4–32.8) | 5.7 (0.7–19.2) |
| Age groups | | | | | |
| 18–24 | 31.6 (19.9–45.2) | 23.2 (13.0–36.4) | 10.7 (4.0–21.9) | 14.3 (6.4–26.2) | 0 (0.0–0.0) |
| 25–34 | 26.5 (16.5–38.6) | 23.5 (14.1–35.4) | 17.2 (8.9–28.7) | 13.8 (6.5–24.7) | 1.6 (0.0–8.8) |
| ≥ 35 | 23.0 (13.2–35.5) | 24.1 (13.9–37.2) | 25.0 (14.4–38.4) | 18.2 (9.1–30.9) | 8.9 (3.0–19.6) |
| Diagnoses | | | | | |
| Other ASD diagnosis | 29.5 (19.7–40.9) | 27.0 (17.4–38.6) | 18.3 (10.1–29.3) | 19.7 (11.2–30.9) | 3.0 (0.4–10.4) |
| Asperger syndrome | 25.0 (17.2–34.3) | 21.3 (14.0–30.2) | 17.1 (10.5–25.7) | 12.4 (6.8–20.2) | 3.8 (1.1–9.6) |
| Intellectual functioning | | | | | |
| IQ < 85 | 34.0 (21.5–48.3) | 25.0 (13.6–39.6) | 18.8 (8.9–32.6) | 20.8 (10.5–35.0) | 2.2 (0.1–11.8) |
| IQ ≥ 85 | 23.8 (16.5–32.3) | 19.8 (13.1–28.1) | 16.9 (10.7–25.0) | 12.7 (7.3–20.1) | 3.4 (0.9–8.5) |
| Level of education | | | | | |
| Low | 32.1 (19.9–46.3) | 31.4 (19.1–45.9) | 18.4 (8.8–32.0) | 22.4 (11.8–36.6) | 4.4 (0.5–15.2) |
| Medium | 26.5 (14.9–41.1) | 24.5 (13.3–38.9) | 15.2 (6.3–28.9) | 17.0 (7.6–30.8) | 4.3 (0.5–14.8) |
| High | 23.8 (15.1–34.4) | 18.3 (10.6–28.4) | 18.5 (10.8–28.7) | 10.0 (4.4–18.8) | 2.5 (0.3–8.7) |
| Overall | 26.9 (20.7–33.9) | 23.6 (17.7–30.5) | 17.6 (12.3–24.1) | 15.3 (10.4–21.5) | 3.5 (1.3–7.5) |
CAM use in patients with depression found a prevalence 10–30% in depressive disorder, and of 20–50% in bipolar disorder [50]. In a Finnish study in adults aged 30 years and older, participants with anxiety disorder reported a CAM utilisation prevalence (last 12 months) of 45% [51], while a representative study from the UK found a 12-months-CAM utilisation prevalence of 35% in respondents with anxiety or depression. In comparison to the afore-mentioned studies, our findings lie in the upper half of the reported range. The comparably high prevalence of CAM use in ASD may reflect the presently “incurable” nature of ASD core symptoms, in contrast to other psychiatric disorders where the core symptoms might be addressed successfully through e.g. pharmacotherapy or psychotherapy.

Concerning CAM use in children and adolescents with ASD, there exists a considerable body of literature. A systematic review of 20 studies with a total of 9540 participants found CAM use ranging from 28 to 95% in children and adolescents [10], with special diets and dietary supplements being most frequently utilized. In a more recent German survey of caregivers of children and adolescents with ASD, 46.3% acknowledged current or lifetime CAM use [52]. The similarity between CAM use in children and adolescents, and in adults is noteworthy, as one might expect higher CAM use in adults, who have a higher degree of freedom to decide which therapeutic options to use.

It is also worth comparing the CAM use prevalence found in this study with the prevalence of psychopharmacotherapy utilisation in adults with ASD. The most comprehensive review so far, by Jobski et al. [22], analysed 47 studies from a time period of more than 30 years, including more than 300,000 patients with ASD. In this review, the median for psychopharmacotherapy utilisation in adults with ASD was 61.5%, thus lying clearly above the figure for CAM use in our study.

Regarding potential predictors of CAM use, in our study none of these showed a significant association with either lifetime or current CAM utilisation. The reason for this lack of predictors, which differs from other studies, which found e.g. female gender and higher education to be predictors for CAM use, is not clear. Probably both the relatively small sample size and the selection bias of the sample, namely a significant portion of patients with a diagnosis of Asperger syndrome, have contributed to these inconclusive findings.

As to the CAM modalities being used most frequently, in this study alternative medical systems (e.g. homeopathy, acupuncture), and mind-body interventions (e.g. yoga, music therapy) were the leading modalities. This stands in contrast to CAM use in children and adolescents with ASD, where – as mentioned above – special diets and dietary supplements are the most frequently utilized CAM modality. This difference may be explained by the fact that the postulated mode of action for diets in ASD often addresses improvements within the developing brain, which is more attractive for parents of children with ASD than for affected adult individuals. Moreover, intervention like yoga are often better accessible for adults than for children. Nevertheless, it has to be kept in mind that the term “CAM” denotes a very heterogeneous group of modalities, with different studies using differing definitions of CAM subgroups, thus making a clear delimitation of CAM subgroups difficult.

Finally, this study found 19.8% of respondents being willing to try CAM in the future. This figure is difficult to interpret, as it is unclear whether this reflects a positive attitude towards CAM without prior CAM experiences, or discontent with prior CAM use in 80% of respondents.

As mentioned above, the relatively high CAM utilisation prevalence found in this study possibility reflects at least partly the burden caused by the reduced quality of life of individuals with ASD, and the lack of a causal treatment for this condition. In this context, affected individuals might perceive CAM treatments as a last resort. To help them avoid choosing potentially harmful CAM treatments, guidelines for the management of ASD [53] should offer both professionals and patients clear information on effective, non-effective, and even harmful treatments.

**Strengths and limitations**

To our knowledge, this study is the first survey ever to evaluate CAM use in a population of adults with ASD, which constitutes a major strength. Moreover, the underlying sample includes a reasonable mixture of ASD subtypes, with high diagnostic quality.

Nevertheless, this study also has several limitations: First, CAM use was evaluated through a self-report questionnaire. Still, using self-report instruments on CAM use may induce more honest answers than face-to-face interviews [54]. Second, because of the (for the sake of brevity) non-exhaustive list of CAM modalities presented in the questionnaire, CAM use may have been underestimated. Third, respondents’ reports of lifetime and past CAM use may have been impacted by recall bias. Fourth, the questionnaire employed did not ask about patients’ satisfaction or symptom improvement with CAM treatments [49]. Fifth, in view of age differences between respondents and non-respondents, selection bias cannot be excluded. However, regarding CAM use we did not find any differences by age. Moreover, we did not evaluate respondents’ medication or comorbidities. Finally, patients for this study were recruited at four highly specialised outpatient clinics, so the sample composition may not be representative for the population of adult ASD patients in Germany in general.
Conclusion
This is the first study on CAM use in adults with autism spectrum disorder, demonstrating a considerable prevalence of CAM use in this population. Considering its popularity, health professionals should be aware of the significant prevalence of CAM use in adults with ASD, especially as CAM use is often not disclosed to physicians. Also, patients should be encouraged to critically evaluate information about the effectiveness and potentially dangerous side effects of CAM treatments, as evidence for the majority of these treatments in ASD is still limited.

Abbreviations
ADIR: Autism diagnostic interview – revised; ADOS: Autism diagnostic observation schedule; ASD: Autism spectrum disorder; CAM: Complementary and alternative medicine; CI: Confidence interval; CSRI: Client service receipt inventory; eCRF: electronic case report form; ICD-10: International statistical classification of diseases and related health problems – 10th revision; ID: Intellectual disability; ISCED: International standard classification of education; LD: Learning disability; NCCAM: National center for complementary and integrative health; OR: Odds ratio; PDD-NOS: Pervasive developmental disorder - not otherwise specified; SAS: Statistical analysis software; SD: Standard deviation; UK: United Kingdom; USA: United States of America

Acknowledgements
The authors would like to thank Marie Kollarczyk, Imke Garten, Gerti Gerber, Friederike Helbig and Miriam-Sophie Petasch for their assistance in the conduct of this research and the respondents for participating in this study.

Funding
This work was funded by the German Federal Ministry of Education and Research (FKZ 01EE14009f). The funding organization had no influence on the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.

Availability of data and materials
All data generated or analysed during this study are included in this published article.

Authors’ contributions
JH, FH and CJB conceived of the study, participated in its design and coordination and drafted the manuscript; JH and FH performed the statistical analysis and interpretation of the data; IDK, LP, SR, VR, CK, SS and NW participated in the coordination of the study and performed the measurements. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study protocol was reviewed and approved by the Commission for Impact Assessment Research and Ethics, Carl von Ossietzky University Oldenburg (reference number DRs. 23/2015), and by the concerned institutional ethic committees (Heidelberg University: reference number 2015–607 N-MA; Marburg University: reference number 148/15; Berlin University: reference number 941/15; Dresden University: reference number EK601,2016). The data protection concept was additionally coordinated with the Data Protection Officer of the Carl von Ossietzky University, Oldenburg. All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Ammerländer Heerstraße 140, 26129 Oldenburg, Germany.
2. Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Philipps University Marburg, Hans-Sachs-Str. 4, 35039 Marburg, Germany.
3. Department of Psychiatry, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany.
4. Department of Child and Adolescent Psychiatry, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075 Göttingen, Germany.
5. Department of Child and Adolescent Psychiatry, Medical Faculty of the Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
6. Department of Child and Adolescent Psychiatry, LVR-Klinikum Düsseldorf/Heinrich-Heine University Düsseldorf, Bergische Landstr. 2, 40629 Düsseldorf, Germany.

Received: 20 November 2018 Accepted: 28 January 2019
Published online: 01 February 2019

References
1. WHO. Traditional Medicine: Definitions [Internet]. World Health Organization; 2000 [cited 2015 Sep 8]. Available from: http://www.who.int/medicines/areas/traditional/definitions/en/
2. National Center for Complementary and Integrative Health. Complementary, Alternative, or Integrative Health: What’s in a Name? [Internet]. 2016. Available from: https://nccih.nih.gov/health/integrative-health
3. Harris PE, Cooper KL, Retton C, Thomas KJ. Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update. Int J Clin Pract. 2012;66:39–49.
4. McFarland B, Bigelow D, Zani B, Newcomb J, Kaplan M. Complementary and alternative medicine use in Canada and the United States. Am J Public Health American Public Health Association. 2002;92(18):1616–8.
5. Marstedt G, Moebus S. Inanspruchnahme alternativer Methoden in der Medizin. Robert Koch Institut, Statistisches Bundesamt, editors. Gesundheitsberichterstattung des Bundes. 2003:9.
6. Millar WJ. Patterns of use–alternative health care practitioners. Heal reports. 2001 Dec;13(1):9–21.
7. Hansen B, Grimmel S, Laursen L, Fønnebø V, Falkenberg T, Rasmussen NK. Use of complementary and alternative medicine in the Scandinavian countries. Scand J Prim Health Care. 2005 Mar;23(1):57–62.
8. Pedersen CG, Christensen S, Jensen AB, Zachariae R. Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer. 2009 Dec;45(18):3172–81.
9. Bahceci B, Bagiccioglu E, Ozturk A, Bulbul F, Sahiner IV, Tunper BE, et al. Complementary and alternative medicine use in patients with mental disorders in Turkey. Complement Ther Clin Pract. 2013 Nov;19(4):221–6.
10. Höfer J, Hoffmann F, Bachmann C. Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: a systematic review. Autism. 2017;21(4):387–402.
11. Feng L, Chiam PC, Kua E-H, Ng TP. Use of complementary and alternative medicines and mental disorders in community-living Asian older adults. Arch Gerontol Geriatr. 50(3):243–8.
12. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;12:1–23.
13. Nilsson J, Källman M, Östlund U, Holgersson G, Bergqvist M, Bergström S. The use of Complementary and alternative medicine in Scandinavia. Anticancer Res. 2016;36(7):3243–51.
14. Metcalfe A, Williams J, McChesney J, Patten SB, Jette N. Use of complementary and alternative medicine by those with a chronic disease and the general population—results of a national population based survey. BMC Complement Altern Med. 2010;10(1):58.
15. American Psychiatric Association. DSM-V. In: American journal of psychiatry; 2013.
16. La M-C, Lombardo MV, Autism B-CS. Lancet. 2014;383(9920):896–901.
17. Brugha TS, McManus S, Barkant J, Scott F, Purdon S, Smith J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry. 2011.
18. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years —
Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill Summ. 2018 Apr 27;67(6):1–23.

19. Bachmann CJ, Gerste B, Hoffmann F. Diagnoses of autism spectrum disorders in Germany: time trends in administrative prevalence and diagnostic stability. Autism. 2018;22(3):283–90.

20. Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011–2012. Natl Health Stat Report 2013;65(1):1–12.

21. Kamp-Becker I, Poustka L, Bachmann C, Erflich S, Hoffmann F, Känkie P, et al. Study protocol of the ASD-net, the German research consortium for the study of Autism Spectrum Disorder across the lifespan: from a better etiological understanding, through valid diagnosis, to more effective health care. BMC Psychiatry. 2017;17(1):206.

22. Jobkšk J, Höfer J, Hoffmann F, Bachmann C. Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review. Acta Psychiatr Scand. 2017 Jan;135(1):8–28.

23. Frye RE, Slattery J, Delhey L, Furgeson B, Strickland T, Tippett M, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018.

24. Gabriels RL, Pan Z, Dechant B, Agnew JA, Brim N, Mesibov G. Randomized controlled trial of therapeutic horseback riding in children and adolescents with Autism Spectrum disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(7):541–9.

25. Brondino N, Fusar-Poli L, Rocchetti M, Provenzani U, Barale F, Politi P. Complementary and Alternative Therapies for Autism Spectrum Disorder. Evid based complement Alternat med. Hindawi Limited; 2015;2015:2588589.

26. DeFilippi M. The use of Complementary alternative medicine in children and adolescents with Autism Spectrum Disorder. Psychopharmacol Bull. 2018;48(1):40–63.

27. Levy SE, Hyman SL. Complementary and alternative medicine treatments and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1992. p. 163

28. Bent S, Hendren RL, Zandi T, Law K, Choi J-E, Widjaja F, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(2):236–49.

29. Rey JM, Walter G, Soh N. Complementary and alternative medicine (CAM)–treatments and pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2008;47(6):364–8.

30. Bölte S, Rühl D, Schmötzer G, ADI-R PF. Diagnostisches Interview für Autismus - Revidiert. Deutsche Fassung des Autism Diagnostic Interview - Revised von Michael Rutter, Ann Le Couteur und Catherine Lord. 1. Auflage. Bern: Hans Huber; 2004.

31. Rühl D, Bölte S, Feinein-Metthews S, Poustka FADOS. Diagnostische Beobachtungsskala für Autistische Störungen. 1. Auflage. Bern: Hans Huber; 2006.

32. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, Beecham J, Jackson BL, editors. Measuring mental health needs. Measuring. London: the Royal College of psychiatrists; 1992. p. 163

33. National Institutes of Health. Complementary and Alternative Medicine [Internet]. U.S. National Library of Medicine; 2003 [cited 2018 Jan 22]. Available from: https://www.nlm.nih.gov/tsd/acquisitions/cdm/subjects24.html

34. UNESCO. International standard classification of education ISCED 1997. Paris: UNESCO; 1997.

35. UNESCO. International Standard. Classification of education ISCED 2011. Montreal: UNESCO Institute for Statistics; 2012.

36. Schroeder JH, Lechert Y, Lüttinger P. Die Umsetzung der Bildungsskala ISCED-1997 für die Volkszählung 1970, die Mikrozensus-Zusatzerhebung – 1971 und die Mikrozensen 1976 – 1980. ZUMA-Methodenbericht, 2006/8. 2011;2006/08/6/67.

37. Schneider S. The international standard classification of education (ISCED-97): an evaluation of content and criterion validity for 15 European countries. Mannheim: Mannheimer Zentrum für Europäische Sozialforschung (MZES); 2008. p. 330.

38. Tewes U. HAWIK-R Hamburg-Wechsler-Intelligenztest für Kinder. Revis Bern Huber; 1983.

39. Dauks HG, Petermann F, Tewes U, Rossmann P, Schallberger U. Hamburg-Wechsler-Intelligenztest für Kinder III (HAWIK-III). Kindheit und Entwicklung. 2004.

40. Petermann F, Petermann U. Wechsler intelligence scale for children (deutsche Ausgabe) - fourth edition. Frankfurt: Pearson Assessment; 2011.

41. Tewes U. Hamburg-Wechsler-Intelligenztest für Erwachsene. Hawie R, Ed Bern Hans Huber; 1991, 1991;